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Introduction: Despite being the 6th cause of cancer death in Australia, cancer of
unknown primary (CUP) site remains poorly understood.
Aims: To describe practices relating to the diagnosis, investigation, classification,
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communication and management of CUP amongst medical oncologists.
Methods: We invited all members of the Medical Oncology Group of Australia to
participate in a national, anonymous online survey about CUP. The survey
collected data regarding diagnosis acceptance, diagnostic tests, treatment
protocols and communication practices around the diagnosis of CUP.
Results: 302 oncologists were invited and 86 (28%) completed the survey.
Eighty respondents (93%) were directly involved in the assessment of patients
with CUP. Eighty-five (99%) respondents were prepared to make a diagnosis of
CUP if, after appropriate diagnostic tests, the primary location could not be
ascertained. 83% would assign a primary site to obtain Pharmaceutical Benefits
Schedule (PBS) funding of medical therapy.

62% did not have a specific

treatment protocol designed for CUP. The majority of oncologists used serum
tumour markers and CT scans in the initial work-up, whilst 43% indicated they
would use a PET scan in the majority of cases. The majority would arrange
mammography in female patients. Thematic analysis of responses to openended questions about how CUP is described identified little consistency in the
language being used.
Conclusion: The approach to diagnosis, investigation and management of CUP
by medical oncologists in Australia is variable. Many preferred to estimate the
primary site and treat accordingly. PBS restrictions may encourage the practice
of ‘best guessing’.
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CUP,

Survey,

Diagnosis,

Failure to determine the site of origin of a cancer, so called cancer of unknown
primary site (CUP), has been recognised as a distinct diagnostic entity for over
30 years(1). There are no distinguishing clinical signs or symptoms to denote the
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primary location of the cancer. Epidemiologic studies have reported that CUP
represents between 2 to 5% of all cancer diagnoses(2) (3). In 2011,
approximately 2,800 Australians received a new diagnosis of CUP. This was the
12th most commonly diagnosed cancer in men and 11th in women(4). CUP is
typically associated with a poor survival, and in 2012 it was the 6th most
common cause of cancer related death (4) .
Recent epidemiological data from the USA and Australia indicate that the
incidence of CUP has declined,(4, 5) An analysis of the Surveillance,
Epidemiology and End Results (SEER) database in the United States revealed a
proportional decline in CUP since 2007 to less than 2% of all cancer diagnoses(6).
This decrease may reflect changing clinical diagnostic criteria and reporting
practices(7).
Poor acceptance or lack of acknowledgement of a diagnosis of CUP may
contribute to an under-reporting of the diagnosis to cancer registries. Whilst in
recent years the utilisation of more sensitive radiological procedures, including
MRI, fine slice CT scan and positron emission tomography (PET) scanning has
increased the detection rate of primary cancers, for the majority of CUP cases the
primary cancer remains elusive(8, 9). Doubt regarding the utility and cost
effectiveness of these diagnostic procedures for CUP remains, but they may be
performed on an individual indication basis(10, 11). Immunohistochemical
staining of pathology slides has also helped clinicians in ascribing a probable site
of origin(12). Most recently the use of gene expression profiling to develop tissue
of origin assays has increased the ability to assign the most likely primary
site(13-18). Despite technological advancements and increased sophistication in
the analysis and interpretation of these findings, there usually remains a margin
of uncertainty.
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Arguably, the diagnosis and management of CUP is one of the most difficult
challenges in oncology. Overall, the prognosis for patients with CUP is poor. A
recent population-based US registry analysis of adenocarcinoma of unknown
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primary revealed only a marginal improvement in survival between 1973 and
2008(6). The diagnosis of CUP commonly confuses and frustrates patients, their
carers and their doctors. The inability to identify a primary may be seen as a
failure of the diagnostic process. Moreover, patients understand that treatment
is usually selected according to the site of origin of the malignancy. If a site is not
identified, then patients may feel that accurate and optimal treatment selection
is not possible.
In many parts of the world, including Australia, access to cancer therapies is
regulated. In Australia, access to cancer therapies is funded by government
through the public-access Pharmaceutical Benefits Scheme (PBS). The PBS
enables subsidised access to relatively expensive cancer treatments for all
Australians. Funding approval requires the doctor to gain authority to prescribe
particular drugs for specified diagnoses and clinical situations. Consequently,
oncologists may decide to assign an originating cancer site, so as to enable access
to drugs to treat the CUP.
The aim of this study was to assess diagnosis acceptance, diagnostic tests and
treatment protocols, as well as communication and documentation practices,
amongst a representative sample of Australian medical oncologists.

Methods
Sample
A total of 302 members of the Medical Oncology Group of Australia, who
comprise the majority of medical oncologists in Australia, were invited to
complete an on-line survey.
Measures
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The survey comprised 14 closed-response questions, and 2 open-ended
questions and one categorical question with a comment option. The survey was
pilot tested by the CUP steering committee coordinated by the Cancer Council
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NSW and the wording of items was altered in response to feedback. The survey
evaluated oncologists’ understanding of CUP and assessed recognition of the
diagnosis. The survey also explored the investigations and procedures
commonly performed, the treatment protocols utilised, and clinical practices
such as communication strategies in the management of CUP. In addition, we
asked about the diagnostic assignment, particularly with reference to accessing
cancer medication on the PBS, an Australian Commonwealth government funded
drug access program. The open-ended questions were designed to explore the
language medical oncologists used to describe CUP and how the diagnosis is
communicated and discussed. The open ended questions were ‘How do you
describe or discuss a diagnosis with patients and families? Is CUP a term
that you use? Please give a brief description”; and “Cancer of Unknown
Primary is a difficult diagnosis to explain. How do you discuss it?” A copy of
the questionnaire is provided in the online Supplement
Procedures
Members of the Medical Oncology Group of Australia were sent an invitation by
e-mail, inviting them to complete an online survey. The invitation was initially
sent on March 2012 with a reminder email sent in May 2012. The survey was
expected to take 10 minutes to complete.
Analysis
Descriptive statistics were used to summarise the survey data. A qualitative
content analysis of the open-ended questions and of comments provided was
also performed. The data was inserted into an Excel spreadsheet and two data
coders (LG and PS) individually analysed to identify themes and sub-themes.
The two sets of categorisations were compared and disagreements discussed
until agreement was reached.

Results
This article is protected by copyright. All rights reserved.

A total of eighty-six oncologists completed the survey (response rate 28%).
Eighty of the respondents confirmed their direct involvement in the assessment
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of patients with CUP.
Participant demographics are presented in Table 1. Seventy-seven of the
respondents were based in a metropolitan centre and 70 listed a public hospital
or clinic as their principal place of work. The remaining 16 were based in private
clinics.
Almost all survey respondents (99%) stated they were prepared to make a final
diagnosis of CUP if after appropriate diagnostic tests the primary site remained
uncertain. However, when asked a different question that explored oncologists’
preference rather than willingness, 27% stated that they would prefer to provide
a best guess of the primary site of the cancer, rather than diagnose CUP as a
specific diagnostic entity, while a further 33% said that they would sometimes
do this.
When asked specifically about accessing cancer therapies through the PBS, 83%
(71/86) of respondents stated that they document a possible primary location of
the cancer and define the cancer as such, to obtain PBS funding of a medical
therapy for patients with CUP. Only 15 of the respondents said that they do not
do this.
The vast majority (98%) disagreed “that all CUP cancers are the same entity”.
Approximately half (51%) responded ‘yes’ to the question “Do you have a
specific diagnostic process for patients that present with CUP?” and 62%
(53/86) stated they did not have a specific treatment protocol designed for
patients with CUP at their institution.
The majority of medical oncologists used serum tumour markers and CT scan
imaging in the initial diagnostic evaluation of suspected CUP, whilst 43%
indicated they would use a PET scan in at least 50% of cases. 64% stated that
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they would arrange mammography in more than 90% of cases of female patients
with suspected CUP. Medical oncologists performed the following investigations
in the majority (> 50%) of CUP patients; tumour markers (88%), CT scan (98%),
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mammography in female patients (85%) and gastrointestinal endoscopy (60%).
When medical oncologists were asked about investigations they perform in the
vast majority (> 90%) of CUP patients, only three investigations were included:
tumour markers (67%), CT scan (91%), mammography in female patients (64%).
The preferred investigations for CUP are depicted in figure 1.
When asked about PET scan use to identify the primary site, 16% of respondents
would arrange a PET scan in > 90% of CUP cases, 41% of respondents would
arrange a PET scan in > 50% of CUP cases and the majority either do not utilise
PET, or use PET in fewer than 50% of cases.
Theme 1: Language to describe CUP
The primary tumour has regressed or is too small
Clinicians that used the term CUP with their patients also often used the analogy
of the primary tumour regressing and hence being undetectable. Several
clinicians reported explaining to patients that “Primary (parent) appears to have
regressed but metastases (children) have grown”, they “explain how in
approximately 5% of cases we never can find the primary as it may be too small to
visualise before it sends off metastatic cancer cells to other organs” and “in a
percentage of patients we cannot find the primary site as it may have regressed or
is not able to be found by conventional diagnostic means”. A medical oncologist
also reported using this scenario and further elaborating to explain, “there are a
small number of patients where this happens and it is called ‘cancer of unknown
primary’”.
Uncertainty
There is also considerable reference to uncertainty when explaining CUP to
patients and family. It is a common subtheme used by medical oncologists both
with and without the definitive use of the word CUP. Medical oncologists noted
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describing CUP as “Cancer that has started in the body and spread but not sure
where in the body it started”, “occasionally we remain uncertain of where cancer
started even after all tests are complete” and also “ explain that [it is] uncertain as
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to where primary malignancy commenced and that sometimes this is the case with
cancer”.
Poor prognosis
A minority of medical oncologists reported discussing the diagnosis in terms of
its poor prognosis, for example; “whilst we can offer chemotherapy, it is not
curable and prognosis is often in the realm of months rather than years”; and “this
is a worse prognostic group with a particularly short survival”; “CUP is generally
not curable except in occasional circumstances”. Another similar recorded
response was; “I believe that true CUP is a syndrome with median survival 6
months no matter what you do”. Clinicians that did not use the term CUP also
described the diagnosis in terms of the associated poor prognosis; “I provide a
general description of the behavior of the cancer and the poor prognosis”.
‘Best guess’ diagnosis
The use of a ‘best guess’ approach was also reported amongst clinicians who use
the term CUP and those who do not. “No I don’t use CUP; I usually talk about my
best guess primary” and “CUP is a term that I do use, but I try to give information
about the most likely primary site based on pathological findings”. There were
several responses that incorporated a best guess in their description of a likely
diagnosis when explaining CUP to their patients, “I divide the body into regions,
discuss tissue diagnosis and exclude what we can as a primary”; “I provide a
possible origin or most likely site of primary tumour”.
Common cancer diagnosis
Some responses demonstrated efforts to promote an understanding that this is a
recognised common cancer type, I “do tell patients that CUP is a reality and more
common than one might think”, “it is not unusual to have cancer spread without
knowing where it has come from”, I “explain that is not uncommon” and I “stress
that it is an entity that accounts for up to 5% of cancer diagnoses”.
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Theme 2: Treatment approaches
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‘Best guess’ to guide treatment
When discussing treatment options to CUP patients, a common subtheme was
using the ‘best guess’ of the primary site to guide treatment choice. Medical
oncologists reported that they “explain the uncertainty about diagnosis and best
guess the treatment option”, “anti-cancer treatment, if appropriate, is based on
best guess according to clinical pattern” and the “need to treat with a best guess
approach”. It was also reported that other clinical information is often used to
guide this approach; I “discuss patient presentation, test results and outcomes and
best fit chemotherapy for the situation” and “options are based on the location of
the disease and likely best fit pattern to determine treatment choice”. This
approach indicates the use of best clinical judgement in the face of uncertainty.
The ‘best guess’ is based on all available clinical, radiological and
histopathological information.
Broad-based therapy and treatments that ‘work’
Medical oncologists also reported explaining the use of treatment effective
against a broad spectrum of cancers as opposed to therapies typically used to
treat particular cancer types; “There are a small proportion of cancers we are
unable to find a primary for and we use therapies which are broad spectrum to
give them the best result.”; “there are drugs with broader spectrum that may cover
a number or possibilities” and “the initial site of the cancer can’t be found at this
time, so we need to choose drugs that will work across a range of cancers”.
Some medical oncologists were positive about the effectiveness of therapy
despite the inability to identify a primary; “we sometimes never find the origin of
the cancer and it is usually widespread at diagnosis. It can respond well to
treatment”. Some were also reassuring patients that there were alternative
treatments if the initial treatment was ineffective; “it is still possible to provide
treatment and that treatment can be changed to alternative treatment if it is not
helping”.
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Theme 3: Communication challenges
Clinician skill and time
Clinician skill, and allocating sufficient time, was highlighted as important in
overcoming communication challenges inherent in a CUP diagnosis. Medical
oncologists reported the explanation of CUP to be a “discussion [that] is long and
involved”, “not easily explained in a short comment”, and “takes great skill,
experience, knowledge, empathy and time”.
Patient ability to understand
A clinician’s use of the term CUP was reported to dependent of the patients’ level
of understanding; I “sometimes use ‘CUP’ terminology – depending on patient level
of understanding”. It was also reported that a diagnosis of CUP was “not difficult
to explain but difficult for patients and families to understand/accept”.

Discussion
CUP presents a wide diversity in diagnostic and treatment pathways. In the
majority of cases, CUP represents a cancer (or a group of cancers) with multiple
sites of involvement, displaying relatively aggressive biological behaviour and
associated with a poor prognosis, but favourable prognostic subsets are
recognised(19-21) (22). Given the complexity around the diagnosis, and the
negative connotations associated with terms of uncertainty such as ‘unknown’,
some experts in the field have recommended changing the diagnostic term to
“Cancer of Complex Origin”(23). Our survey indicates that the language around
CUP and medical oncologists’ approach to the initial diagnosis, investigation and
management of CUP in Australia is variable. To our knowledge this is the first
attempt to understand how oncologists manage CUP clinically and the challenges
that they face. We are not aware of any similar published data that we can
compare our results to.
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Many clinicians preferred to use of best clinical judgement to guess the primary
site of the cancer and treat accordingly. In Australia, PBS restrictions to drug
access appear to encourage the practice of ‘best guessing’ the primary site of
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cancer origin and assigning a diagnosis when requesting subsidised drug access
via the PBS. The PBS restrictions otherwise prejudice CUP patients accessing
potentially effective treatments. Acceptance of the CUP diagnosis was not
universal amongst Australian oncologists. This may have implications regarding
the accuracy of site-specific cancer registry data in Australia.
Variability was observed in the selection of the preferred initial investigations.
CT scans, serum tumour markers, GI endoscopy and mammography (for female
patients) are investigations that oncologists said that they performed in the
majority of cases. PET scanning is used in less than 50% of cases. A high degree
of variability in the selection of investigations for the evaluation of CUP has
previously been reported(1, 24). In recent years, however, attempts to
standardise the management of patients with CUP have been published based in
the form guidelines produced by the NCCN (National Comprehensive Cancer
Network) and the European Society of Medical Oncology(25, 26).

These

guidelines are based on evidence and consensus, but several areas remain
contentious. The utility of PET in this setting, for example, remains debatable.
Some authors have reported a high rate (> 50%) of primary lesion detection
through the application of FDG-PET/CT scans (27, 28). Others have reported a
sensitivity of less than 50% (9, 29). A recent study observed a high sensitivity,
but low specificity in detecting the primary through PET in patients presenting
with CUP in cervical nodes, and it is in this group that the guidelines recommend
use of PET/CT (30) .
Most oncologists surveyed stated that their institutions did not have CUP specific
treatment protocols. This may be attributable to the absence of a globally
accepted regimen. The approach to the treatment of CUP is evolving with the
expectation that molecular analysis of the tumour will help identify genetic
alterations for which there are specific targeted therapies. Indeed, a recent study
reported a high rate of detectable genetic alterations in CUP specimens, the
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majority of which were found to be amenable to a molecular targeted treatment
strategy(31). Our survey did not specifically explore the utilisation of molecular
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testing in the assessment of CUP.
Limitations
A response rate of 28% is low and we acknowledge that there is likely to be bias
in the responses obtained. Of the respondents within this sample, 94% of
medical oncologists were involved in the assessment of patients during the
diagnosis of CUP; therefore data collected in this survey is biased towards
oncologists that treat CUP. However, we believe that this is the only data
available that assess diagnosis acceptance, diagnostic tests selected and
treatment protocols used by medical oncologists. The assessment of the
communication and documentation practices in relation to the CUP diagnosis
also provides valuable insights into clinical practice and this has never been
previously investigated or reported.

Conclusion
The survey highlighted that CUP is a diagnosis that is accepted by oncologists but
the majority would be prepared to provide a ‘best guess’ of the primary site in
order to access drugs on the PBS and provide affordable treatment to patients.
The management of patients with CUP is variable, as is the clinical presentation.
The use of existing clinical practice guidelines may help Australian clinicians
manage this complex malignancy.
Acknowledgement:
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Table 1. Demographics of participating medical oncologists.
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Oncologists
(N= 86)
Age (years)
•

Less than 40

30 (35%)

•

40-49

25 (29%)

•

50-59

24 (28%)

•

>60

7 (8%)

Principal work location
•

Public Hospital/Public Clinic – Capital City

65 (75%)

•

Private Hospital/Private Clinic – Capital City

12 (14%)

•

Public Hospital/Clinic – Regional

5 (6%)

•

Private Hospital/Private Clinic – Regional

4 (5%)

State or Territory
5 (6%)

•

Australian Capital Territory

•

New South Wales

21 (24%)

•

Victoria

30 (35%)

•

Queensland

10 (12%)

•

South Australia

11 (13%)

•

Western Australia

3 (3%)

•

Tasmania

6 (7%)

•

Northern Territory

0 (0%)
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